Physician Photo

Robert Paul Hasserjian, MD

Associate Pathologist, Massachusetts General Hospital

Director, Hematopathology Fellowship Program, Pathology Service

Associate Professor of Pathology, Harvard Medical School

Dr. Hasserjian works closely with oncologists and other hematologists to provide optimal patient care. He lectures regularly at continuing medical education courses at medical schools throughout the United States.

Department of Pathology


  • Cancer Center
  • Leukemia
Clinical Interests
Gastrointestinal (GI) pathology
Boston: Massachusetts General Hospital
Medical Education
MD, Harvard Medical School
Residency, Brigham and Women's Hospital
Fellowship, Brigham and Women's Hospital
Board Certifications
Anatomic Pathology, American Board of Pathology
Hematology, American Board of Pathology
Foreign Languages
Patient Age Group
Adult and pediatric
Accepting New Patients
Accepting New Patients


Dr. Hasserjian's clinical work and research focus on myeloid neoplasia.  He has served on the Executive Committee of the Society for Hematopathology and on the Education Committee of the United States and Canadian Academy of Pathology. Dr. Hasserjian is a member of the Pathology Advisory Committee for the World Health Organization Classification of Myeloid Neoplasms. Dr. Hasserjian is a dedicated medical educator, and director of the Hematopathology Fellowship at Massachusetts General Hospital.


Dr. Hasserjian's research interests include:

  • Molecular mechanisms of leukemia and lymphoma.
  • Novel pathologic, immunophenotypic, and molecular prognostic markers in myelodysplastic and myeloproliferative diseases, leukemias, and lymphomas

For more information about research concepts, co-authors, and to see a timeline, visit  Dr. Hasserjian?s profile at the Harvard Clinical and Translational Science Center.


View my most recent publications at PubMed

  1. Chronic lymphocytic leukemia/small lymphocytic lymphoma: another neoplasm related to the B-cell follicle? Tandon B, Swerdlow SH, Hasserjian RP, Surti U, Gibson SE.Leuk Lymphoma. 2015 Apr 10:1-33. [Epub ahead of print]
  2. Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. Nardi V, Pulluqi O, Abramson JS, Dal Cin P, Hasserjian RP.  Am J Hematol. 2015 Mar 16.[Epub ahead of print]
  3. Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, Fauble V, Finazzi G, Pane F, Mascarenhas J, Prchal J, Giralt S, Hoffman R. Bone Marrow Transplant. 2015 Feb 9. doi: 10.1038/bmt.2014.323. [Epub ahead of print]

Pathology Associates
55 Fruit Street
Boston, MA 02114-2696

Phone: 617-724-1445
Fax: 617-726-7474